Don’t mind the gap risk: regulatory treatment of credit repacks

§ 01 Executive Snapshot

• What: Discussion of gap risk in credit repackaging and its regulatory implications under Basel III.
• Who: Senior quant Andrey Chirikhin.
• Why it matters: Clarifying the regulatory treatment of gap risk could impact how credit repackaging products are valued and managed in the financial markets.

§ 02 Key Developments

• Credit repackaging has gained traction as a yield enhancement strategy for investors, emphasizing the need for accurate gap risk valuation.
• The industry is debating whether gap risk constitutes a credit valuation adjustment (CVA) under Basel III regulations.
• The article highlights potential misunderstandings surrounding the regulatory classification of gap risk in the context of credit repacks.

§ 03 Strategic Context

• Credit repackaging has evolved as a popular financial instrument, particularly in low-yield environments, necessitating a clear understanding of associated risks.
• Basel III regulations have introduced more stringent capital requirements, creating a pressing need for clarity in how various risks, including gap risk, are treated.

§ 04 Strategic Implications

• Misclassification of gap risk could lead to improper capital allocation and risk management practices within financial institutions.
• Accurate regulatory treatment of gap risk may enhance investor confidence and market stability for credit repackaging products.

§ 05 Risks & Constraints

• Regulatory uncertainty regarding the classification of gap risk poses a challenge for market participants.
• Potential discrepancies in valuation methodologies could lead to inconsistent practices across the industry.

§ 06 Watchlist / Forward Signals

• Upcoming regulatory guidance or clarifications from Basel III authorities regarding the treatment of gap risk.
• Monitoring changes in market practices related to credit repackaging as firms adapt to evolving regulatory expectations.